• Lilly and Alder showcase latest migraine drug data pharmaphorum
    April 26, 2018
    A gang of new migraine drugs are nearing approval, and new data is emerging from contenders from Eli Lilly, and its upstart rival Alder Biopharmaceuticals as they prepare their bids for a highly competitive market.
PharmaSources Customer Service